A hypothetical price of $3 for the Sui (SUI) token in 2027 suggests a fully diluted valuation of $30 billion, which is about 81% higher than the top end of current forecasts that predict a range between $0.864 and $1.661. The forecast average is $1.207, and the $3 figure is a scenario, not a prediction. SUI has a capped supply of 10 billion tokens, and its price affects network transactions and gas fees. The full supply is not yet circulating, and the token’s price reaching $3 is not guaranteed but remains a speculative possibility.
The Sui token's hypothetical $3 price in 2027 is noted alongside Pluang's current market data for context. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 14:01 WIB: out of 50 major cryptocurrencies, 36 rose and 13 fell today. Notable movers include FTM (Fantom) at Rp11.382 with a 1-day change of -2.05% and a typical hold time of 88 days, THETA (Theta Network) at Rp3.369 with a -2.04% change and 78 days hold time, and BCH (Bitcoin Cash) at Rp5.046.725 with a +1.93% change, typical hold time of 69 days, and Pluang order activity showing 77% sell and 23% buy.
Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
